EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
VOLUNTARY ANNOUNCEMENT - THE CENTER FOR DRUG EVALUATION, NMPA GRANTED PRIORITY REVIEW STATUS TO NDA FOR DTCP INFANT
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TETANUS VACCINE
Monthly Return of Equity Issuer on Movements in Securities
INSIDE INFORMATION - RESULTS FORECAST FOR THE YEAR 2024
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT - MENHYCIA OBTAINS DRUG REGISTRATION CERTIFICATE IN INDONESIA
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE I CLINICAL TRIAL FOR RECOMBINANT POLIOMYELITIS VACCINE IN INDONESIA
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II/III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR TDCP ADOLESCENT AND ADULT
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR DTCP INFANT
INSIDE INFORMATION - CHANGE OF INTERESTS OF PARTIES ACTING IN CONCERT
1
2
3
4
5
6
44